MTOR and carcinoma: MEK but not mTOR inhibition in vitro induced cytotoxicity, reduced inflammatory cytokine secretion and CD44 expression and reduced migratory capacity in MOC1 and MOC2 cells, consistent with the Ras-driver mutations shared by these carcinomas.